These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33800950)

  • 1. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
    Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity.
    Stappers F; Scharnetzki D; Schmitz B; Manikowski D; Brand SM; Grobe K; Lenders M; Brand E
    J Inherit Metab Dis; 2020 Mar; 43(2):334-347. PubMed ID: 31587315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease.
    Scharnetzki D; Stappers F; Lenders M; Brand E
    Mol Genet Metab; 2020; 131(1-2):229-234. PubMed ID: 32888778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
    J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.
    Lenders M; Brand E
    Front Immunol; 2022; 13():1024963. PubMed ID: 36569886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
    Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
    Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
    Lenders M; Brand E
    Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
    CEN Case Rep; 2024 Aug; 13(4):290-296. PubMed ID: 38135868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
    PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
    van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
    Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease.
    Lenders M; Feidicker LM; Brand SM; Brand E
    Front Immunol; 2023; 14():1266082. PubMed ID: 37818380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa.
    Lenders M; Pollmann S; Terlinden M; Brand E
    Mol Ther Methods Clin Dev; 2022 Sep; 26():323-330. PubMed ID: 35990747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease.
    Hennermann JB; Arash-Kaps L; Fekete G; Schaaf A; Busch A; Frischmuth T
    J Inherit Metab Dis; 2019 May; 42(3):527-533. PubMed ID: 30746723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
    Linthorst GE; Aerts JM
    J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
    Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
    PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
    Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
    Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
    Lenders M; Stypmann J; Duning T; Schmitz B; Brand SM; Brand E
    J Am Soc Nephrol; 2016 Jan; 27(1):256-64. PubMed ID: 25933799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
    Deegan PB
    J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation.
    van Kuilenburg ABP; Hollak CEM; Travella A; Jacobs M; Gentilini LD; Leen R; der Vlugt KMMG; Stet FSB; Goorden SMI; van der Veen S; Criscuolo M; Papouchado M
    Drugs R D; 2023 Jun; 23(2):141-153. PubMed ID: 37083901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.